Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Depolarizing Blockers: Pharmocokinetics

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Mania and Antimanic Drugs: Overview

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Narrative review of rationale for IV deferoxamine plus intranasal insulin to ameliorate brain damage following resuscitation from cardiac arrest.

Resuscitation plus·2026

Same author

The Implications of Private Equity Investment in Emergency Medicine.

Journal of the American College of Emergency Physicians open·2026

Same author

Artificial Intelligence-powered tiered early warning framework addressing high false alarm rates for in-hospital mortality prediction.

NPJ digital medicine·2026

Same author

Biological Sex Is Associated with Pre-Tibial Subcutaneous Tissue Depth for Intraosseous Catheter Insertion.

The western journal of emergency medicine·2025

Same author

A Rare Case of Miller Fisher Syndrome Following Legionella Pneumonia: Expanding the Spectrum of Post-infectious Neurological Complications.

Cureus·2025

Same author

Physician Orders for Waiting Room Patients: Ethical Considerations.

The western journal of emergency medicine·2025

Search research articles

Related Experiment Video

Updated: Nov 16, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Benign Presentation Following Massive Deutetrabenazine Overdose.

Oluseyi Obadeyi¹, James H Paxton², Sarkis Kouyoumjian²

¹Emergency Medicine, Wayne State University School of Medicine, Detroit, USA.

|February 26, 2021

Summary

Deutetrabenazine (DTBZ) overdose is rare but possible. This case highlights its low toxicity, suggesting a favorable safety profile even in massive ingestions for tardive dyskinesia treatment.

Keywords:

deutetrabenazine overdose side effects tardive dyskinesia toxicity toxicology

More Related Videos

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury

Published on: November 9, 2018

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Related Experiment Videos

Last Updated: Nov 16, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury

Published on: November 9, 2018

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Area of Science:

Neuroscience
Pharmacology

Background:

Deutetrabenazine (DTBZ), a VMAT2 inhibitor, is a first-line treatment for tardive dyskinesia (TD) and shows promise for Huntington's disease chorea.
Vesicular monoamine transporter 2 (VMAT2) inhibition impacts dopamine and other monoamine levels in neuronal vesicles.

Observation:

A 59-year-old woman with a history of TD presented after a massive DTBZ ingestion.
The patient exhibited a relative lack of severe overdose symptoms.

Findings:

Massive DTBZ ingestion resulted in minimal adverse effects, supporting its low toxicity in overdose.
The drug's safety profile appears favorable, even in cases of significant overdose.

Implications:

Emergency physicians should be aware of potential DTBZ overdose symptoms, despite its generally good safety profile.
This case reinforces the understanding of DTBZ's safety and side effect profile in overdose scenarios.